Skip to main content
Norris Cotton Cancer Center
In This Section

New Clinical Trials for January 2016

Konstantin Dragnev, Professor, Cancer Mechanism

    Randomized Phase II study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapy
    Molecular Analysis for Therapy Choice (MATCH)
  • Hanmi Pharmaceutical Co.
    A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive Non-Small Cell Lung Cancer (NSCLC) after treatment with an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI)

Shudong Jiang, Assistant Professor, Cancer Imaging and Radiobiology

  • NIH
    Development of a mobile NIRST breast imaging unit

Peter Kaufman, Associate Professor, Molecular Therapeutics

  • Merck & Company
    A Phase II clinical trial of pembrolizumab (MK-3475) as monotherapy for metastatic Triple-Negative Breast Cancer (mTNBC) (KEYNOTE-086)
    A randomized Phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
  • Eisai
    An open-label, single-arm multicenter Phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in subjects with metastatic Triple-Negative Breast Cancer (mTNBC)

Frederick Lansigan, Assistant Professor, Molecular Therapeutics

  • Pharmaceuticals
    A multicenter, open-label study of the Histone Deacetylase inhibitor (HDACi), abexinostat, in combination with ibrutinib, in subjects with relapsed or refractory lymphomas
  • Gilead Sciences
    A Phase 2, open-label study evaluating the efficacy, safety, tolerability, and pharmacodynamics of GS-9973 in subjects with relapsed or refractory hematologic malignancies

Lionel Lewis, Professor, Molecular Therapeutics

  • AbbVie
    A Phase 1b/2 study of duvelisib and venetoclax in subjects with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, or indolent or aggressive non-Hodgkin lymphoma, who have not previously received a Bcl-2 or Pl3K inhibitor
  • Novartis Pharmaceuticals
    A Phase I, multicenter, open-label, single-sequence drug-drug interaction study to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
  • GSK
    An open-label Phase 1 study to evaluate the effects of Dabrafenib (GSK2118436) on the single dose pharmacokinetics of an OATP1B1/1B3 substrate and of a CYP3A4 substrate in subjects with BRAF V600 mutation positive tumors

Kenneth Meehan, Professor, Immunology and Cancer Immunotherapy

  • DHMC
    Patient and caregiver costs following hematopoietic stem cell transplantation

Tracy Onega, Associate Professor, Cancer Control

  • DHMC
    NCCC registry shared resource

William Rigby, Professor, Immunology and Cancer Immunotherapy

  • AbbVie
    A Phase 3, multicenter, blinded, Long-Term Extension (LTE) study in rheumatoid arthritis subjects who have completed a preceding Phase 3 Randomized Controlled Trial (RCT) with ABT-494
  • AbbVie
    A Phase 3, randomized, double-blind study comparing ABT-494 monotherapy to Methotrexate (MTX) in subjects with moderately to severely active rheumatoid arthritis with inadequate response to MTX

Richard Rothstein, Joseph M. Huber Professor, Cancer Epidemiology

  • BAROnova, Inc.
    Endoscopic treatment for weight reduction in patients with obesity using the transPyloric shuttle system: A multicenter, prospective, randomized, double-blind, sham controlled, parallel-design study